Editas Medicine Inc Insider Trading
Every director, officer and 10% holder of Editas Medicine Inc has to report each trade in its stock within two business days of making it. This is those filings.
EDIT on carbonthat →Purchases and sales
Open-market trades only — the lines where someone chose to buy or sell at the going price.
| Insider | Action | Value |
|---|---|---|
| Amy ParisonSVP, Chief Financial Officer2026-09-03453 shat $3.04 | Sale10b5-1 plan | $1.4K |
| Linda BurklyEVP, CHIEF SCIENTIFIC OFFICER2026-09-03709 shat $3.04 | Sale10b5-1 plan | $2.2K |
| Gilmore Neil O'NeillCEO2026-09-035.1K shat $3.04 | Sale10b5-1 plan | $15.6K |
| Amy ParisonSVP, Chief Financial Officer2026-08-03678 shat $2.58 | Sale10b5-1 plan | $1.7K |
| Linda BurklyEVP, CHIEF SCIENTIFIC OFFICER2026-07-284.9K shat $2.67 | Sale10b5-1 plan | $13.2K |
Source: SEC Form 4 filings, via EDGAR. A derivative line reports the shares underlying an option rather than stock outstanding, so it is marked and is not comparable with the rest. Value is shares times the reported price, and is blank where the filing priced the transaction at zero — a grant costs its recipient nothing. Insiders sell for reasons that have nothing to do with the company, which is why a sale is not read as a signal on its own.
More on EDIT
Follow Editas Medicine Inc (EDIT) by email
New trades in Editas Medicine Inc (EDIT) by members of Congress, insiders and funds, with the rest of the week's filings. One email a week, free.
Unsubscribe with one click from any email.